Carbamazepine cutaneous adverse reactions and HLA gene variation in the Chinese population: a systematic review and meta-analysis.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY Pharmacogenomics Pub Date : 2023-06-01 DOI:10.2217/pgs-2023-0054

Qingli Meng, Hongyan Gu, Qinghua Zhang, Zhanmiao Yi, Dechun Jiang

{"title":"Carbamazepine cutaneous adverse reactions and HLA gene variation in the Chinese population: a systematic review and meta-analysis.","authors":"Qingli Meng, Hongyan Gu, Qinghua Zhang, Zhanmiao Yi, Dechun Jiang","doi":"10.2217/pgs-2023-0054","DOIUrl":null,"url":null,"abstract":"Aim: Examining the association between HLA-A/B alleles and different carbamazepine (CBZ)-induced cutaneous adverse reactions in the Chinese population. Methods: A systematic review and meta-analysis of case-control studies was conducted. A systematic search was conducted of PubMed, Embase, the Cochrane Library, National Knowledge Infrastructure, the Chinese Biomedical Literature database and Wanfang Digital Periodicals. Results: 23 studies with a total of 1174 patients were included. In the Han population, HLA-B*15:02 is significantly associated with the increased risk of CBZ-related Stevens-Johnson syndrome/toxic epidermal necrolysis, and this correlation was not related to geographic distribution. HLA-A*31:01, B*38:02 are associated with CBZ-related maculopapular eruption in South Han population. HLA-A*31:01 is associated with CBZ-DRESS in Taiwan Han population. Conclusion: HLA-B*15:02, A*31:01 and B*38:02 genes were found to be involved in the occurrence of CBZ cutaneous adverse reactions in Han Chinese.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":"24 8","pages":"459-474"},"PeriodicalIF":1.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0054","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Examining the association between HLA-A/B alleles and different carbamazepine (CBZ)-induced cutaneous adverse reactions in the Chinese population. Methods: A systematic review and meta-analysis of case-control studies was conducted. A systematic search was conducted of PubMed, Embase, the Cochrane Library, National Knowledge Infrastructure, the Chinese Biomedical Literature database and Wanfang Digital Periodicals. Results: 23 studies with a total of 1174 patients were included. In the Han population, HLA-B*15:02 is significantly associated with the increased risk of CBZ-related Stevens-Johnson syndrome/toxic epidermal necrolysis, and this correlation was not related to geographic distribution. HLA-A*31:01, B*38:02 are associated with CBZ-related maculopapular eruption in South Han population. HLA-A*31:01 is associated with CBZ-DRESS in Taiwan Han population. Conclusion: HLA-B*15:02, A*31:01 and B*38:02 genes were found to be involved in the occurrence of CBZ cutaneous adverse reactions in Han Chinese.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

卡马西平皮肤不良反应与中国人群HLA基因变异:系统回顾和荟萃分析。

目的:探讨HLA-A/B等位基因与中国人群卡马西平(CBZ)引起的不同皮肤不良反应的关系。方法:对病例对照研究进行系统回顾和荟萃分析。系统检索PubMed、Embase、Cochrane图书馆、国家知识基础设施、中国生物医学文献数据库和万方数字期刊。结果:纳入23项研究，共1174例患者。在汉族人群中，HLA-B*15:02与cbz相关的Stevens-Johnson综合征/中毒性表皮坏死松解的风险增加显著相关，且这种相关性与地理分布无关。HLA-A*31:01, B*38:02与南方汉族人群cbz相关性黄斑丘疹相关。HLA-A*31:01与台湾汉族人群CBZ-DRESS相关。结论:HLA-B*15:02、A*31:01和B*38:02基因参与了汉族人群CBZ皮肤不良反应的发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.